Lutropin Alfa
drugOn this page
Also known as ATC G03 GA GONADOTROPINSLuteinising hormoneLuteinising hormone (human)Lutropin alfa component of pergoverisLutropina alfaLutropine alfaLuveris
Summary
Lutropin Alfa (CHEMBL1201419) is an approved protein (ATC G03GA07) targeting LHCGR; indicated across 4 conditions including female infertility and infertility disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: G03GA07
- Targets: 1 (LHCGR)
- Indications: 4 conditions
- Clinical trials: 11
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201419 |
| Name | Lutropin Alfa |
| Type | Protein |
| Max phase | 4 |
| ATC | G03GA07 |
Also known as: ATC G03 GA GONADOTROPINS, Luteinising hormone, Luteinising hormone (human), Lutropin alfa, Lutropin alfa component of pergoveris, Lutropina alfa, Lutropine alfa, Luveris, LUTROPIN ALFA
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| LHCGR | LH receptor | Full agonist | 10.9 | 0% | P22888 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): LHCGR.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 1 | LHCGR |
| Signaling by GPCR | 1 | LHCGR |
| Class A/1 (Rhodopsin-like receptors) | 1 | LHCGR |
| Hormone ligand-binding receptors | 1 | LHCGR |
| GPCR downstream signalling | 1 | LHCGR |
| G alpha (s) signalling events | 1 | LHCGR |
| GPCR ligand binding | 1 | LHCGR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| ovarian follicle development | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 1 |
| spermatogenesis | 1 |
| male gonad development | 1 |
| hormone-mediated signaling pathway | 1 |
| ovulation cycle process | 1 |
| male genitalia development | 1 |
| positive regulation of inositol trisphosphate biosynthetic process | 1 |
| luteinizing hormone signaling pathway | 1 |
| development of animal secondary male sexual characteristics | 1 |
| cognition | 1 |
| uterus development | 1 |
Indications & clinical
Indications
4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| female infertility | 4 | MONDO:0021124 | EFO:0008560 |
| infertility disorder | 3 | MONDO:0005047 | EFO:0000545 |
| hypogonadism | 2 | MONDO:0002146 | MONDO:0002146 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 5 |
| PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00439829 | PHASE4 | COMPLETED | Synchronization of Follicle Wave Emergence and Ovarian Stimulation |
| NCT01504139 | PHASE4 | COMPLETED | The Luteal Phase After GnRHa Trigger - a Proof of Concept Study |
| NCT02140515 | PHASE4 | UNKNOWN | Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism |
| NCT03177538 | PHASE4 | COMPLETED | Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders |
| NCT05405686 | PHASE4 | WITHDRAWN | Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders |
| NCT06227949 | PHASE3 | NOT_YET_RECRUITING | FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients |
| NCT07340827 | PHASE3 | RECRUITING | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) |
| NCT01029470 | PHASE2 | UNKNOWN | To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation |
| NCT04189133 | PHASE2 | UNKNOWN | Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men |
| NCT04899193 | PHASE1 | COMPLETED | Pergoveris FD and Liquid China BE Study |
| NCT07269327 | PHASE1 | COMPLETED | An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: LHCGR
- Diseases: female infertility, infertility disorder